Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Date:10/13/2008

red to TAXUS (4.1 percent for XIENCE V vs. 6.8 percent for TAXUS, p-value=0.03)*.

-- Low rates of stent thrombosis between one and two years, defined as very late stent thrombosis, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.5 percent for XIENCE V and 0.8 percent for TAXUS). The ARC definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials.

* Event rates are based on Kaplan-Meier estimates; p-values are for descriptive purposes only.

Strong Results in Complex Patients: SPIRIT III Subgroup Analyses

Also presented during TCT, a variety of subgroup analyses from the SPIRIT III trial demonstrated observational evidence of strong performance by XIENCE V in a variety of patients and lesion types that represent complex patients. The results consistently favored XIENCE V compared to TAXUS at two years across multiple subgroups examined, including patients with small vessels and multi-vessel patients. In diabetic patients, the analysis showed there were no observed differences between XIENCE V and TAXUS at two years. The SPIRIT III trial was not designed to analyze statistical differences in any of the patient subgroups, as the sample sizes were too small to draw firm conclusions.

"With the subgroup analysis, we saw encouraging trends of lower event rates between one and two years for patients treated with XIENCE V compared to patients treated with TAXUS, regardless of patient or lesion complexity," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Even though the SPIRIT III trial was not designed for statistical comparisons in subgroups, these positive trends demonstrate that XIENCE V performs in a consistent manner and gives physicians confidence in XIENCE V as they consider what is the most effective treatment for their patients."

About XIENCE V

XIENCE V is used to treat coron
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... VIEW, Calif. , June 3, 2015 /PRNewswire/ ... healthcare sector around the globe and keeping track ... in this competitive market. In particular, ensuring user-friendliness, ... detection sensitivity are the most important factors influencing ... their consumer base. New analysis from ...
(Date:6/3/2015)... MALVERN, Pa. , June 3, 2015  Essential ... today that it has been invited to speak at ... New York city on June 4th.  ... Large Bore closure system, including a review of first ... systems.     MANTA closes femoral arterial punctures ...
(Date:6/3/2015)... aTyr Pharma, Inc. (NASDAQ: LIFE ), a biotherapeutics company ... address rare diseases, today announced the Company,s participation at the ... be held at the Four Seasons Hotel in ... John Mendlein , aTyr,s CEO and Executive Chairman, is scheduled ... CT on Wednesday, June 10, 2015. The presentation will be ...
Breaking Medicine Technology:Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 2Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 3Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 4Essential Medical Inc. Announces Participation in 2015 Jefferies Global Healthcare Conference - NYC 2
(Date:6/3/2015)... 03, 2015 VeoMed and Decker ... online and mobile access to premier Continuing Medical ... of Certification (MOC) activities. , ... courses to Decker’s extensive lists of physicians, residents, ... access to VeoMed’s premier online and live-streamed courses. ...
(Date:6/3/2015)... Washington, DC (PRWEB) June 03, 2015 ... Global Inspire Award at DIA’s upcoming Annual Meeting. DIA’s ... for their leadership, level of excellence, and commitment to ... will receive the President’s Award for Outstanding Contribution to ... and innovative contributions to advancing global health. ...
(Date:6/3/2015)... panel of independent experts has spent weeks considering the ... awards presented tonight at TU-Automotive Detroit 2015. , Naturally, ... can now be revealed as: , Car Maker of ... aside by taking the coveted Car Maker of the ... of expert judges., Stand out comments included: , ...
(Date:6/3/2015)... Pittsburgh, PA (PRWEB) June 03, 2015 ... basis can cause discomfort in the back, neck, shoulders ... or other musculoskeletal injuries. In addition, recent research links ... a number of chronic diseases. Fortunately, three inventors from ... than sit at a desk. , They have developed ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Acne is the ... can be particularly stubborn to eliminate and hard to prevent. ... common in teens and young adults, in the years when ... sebum, or oil,” says Jayme Bashian, director and lead medical ... pimples, blackheads and cysts of acne are caused by oil ...
Breaking Medicine News(10 mins):Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2Health News:Co-discoverer of Ebola Virus and AIDS Pioneer to be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Co-discoverer of Ebola Virus and AIDS Pioneer to be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Back Acne: Tips for Clearer Summer Skin 2Health News:Back Acne: Tips for Clearer Summer Skin 3
... U.S. News Media Group and the National Committee ... edition of America,s Best Health Insurance Plans on ... open-enrollment season, when Americans nationwide prepare to select their ... provides consumers with comprehensive rankings and important detailed information ...
... Nov. 12 Bausch & Lomb, the global eye health ... its Board of Directors. , Mr. Hassan was chairman ... by Merck & Co., Inc. on November 3. Before joining ... as chairman and CEO (from 2001 to 2003) of Pharmacia ...
... her bout with H1N1, made all the worse by chronic asthma ... been following the news about the H1N1 swine flu with some ... And from the many hours talking with infectious-disease specialists, I knew ... might be another flu pandemic, but when . , The ...
... ... holiday recipe for Holly Jolly Biscotti, which showcases the peak-season flavors of Texas citrus and ... to promote a good-for-you diet throughout the holidays not just for yourself, but everyone on ... Dallas, ...
... ... of Fresh Throne are the quickest way to keep any bathroom fit for royalty. During product ... ... brand new, all natural spray shield aimed at protecting against horrible bathroom odors. Just a ...
... 11 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a ... development of drug products that are delivered to and ... delivery technologies, and on the development of its immune ... agreement for Oxoferin(TM), its topical wound healing agent, and ...
Cached Medicine News:Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 2Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 3Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 4Health News:Fred Hassan Joins Bausch & Lomb Board of Directors 2Health News:My 10-Day Ordeal With the Swine Flu 2Health News:My 10-Day Ordeal With the Swine Flu 3Health News:My 10-Day Ordeal With the Swine Flu 4Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 2Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 3Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 4Health News:Fresh Throne Eco-Friendly Bathroom Spray Celebrates Launch by Donating to Salvation Army 2Health News:Nuvo research provides WF10 licensing and development update 2Health News:Nuvo research provides WF10 licensing and development update 3Health News:Nuvo research provides WF10 licensing and development update 4Health News:Nuvo research provides WF10 licensing and development update 5
These backbiters enable simple access to the anterior horn of the meniscus....
ACUFEX Loop Handle. Blunt nose basket punch enables flush contouring of meniscus....
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: